June 14, 2022
Sanofi Canada Furthers Commitment to Canadians Living with Diabetes Through Mental Health Resources Provided by MindBeacon
May 15, 2022
Sarclisa® (isatuximab) Combination Provides Unprecedented Median Progression Free Survival in Patients with Relapsed Multiple Myeloma Receiving a Proteasome Inhibitor Therapy
March 28, 2022
Xenpozyme® (olipudase alfa) Approved in Japan, First and Only Approved Therapy Indicated to Treat Acid Sphingomyelinase Deficiency
No current content.